MCID: CHG001
MIFTS: 66

Chagas Disease

Categories: Infectious diseases, Rare diseases

Aliases & Classifications for Chagas Disease

MalaCards integrated aliases for Chagas Disease:

Name: Chagas Disease 12 74 52 58 54 42 3 3 43 15 71 32
American Trypanosomiasis 12 74 52 58 3 17
Chagas' Disease with Digestive System Involvement 12
Chagas' Disease with Nervous System Involvement 12
Chagas' Disease with Other Organ Involvement 12
South American Trypanosomiasis 52
New World Trypanosomiasis 52
Chagas' Disease 12

Characteristics:

Orphanet epidemiological data:

58
american trypanosomiasis
Inheritance: Not applicable; Prevalence: 6-9/10000 (United States); Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 58  
Rare infectious diseases


Summaries for Chagas Disease

MedlinePlus : 42 What is Chagas disease? Chagas disease, or American trypanosomiasis, is an illness that can cause serious heart and stomach problems. It is caused by a parasite. Chagas disease is common in Latin America, especially in poor, rural areas. It can also be found in the United States, most often in people who were infected before they moved to the U.S. What causes Chagas disease? Chagas disease is caused by the Trypanosoma cruzi parasite. It is usually spread by infected blood-sucking bugs called triatomine bugs. They are also known as "kissing bugs" because they often bite people's faces. When of these bugs bites you, it leaves behind infected waste. You can become infected if you rub the waste in your eyes or nose, the bite wound, or a cut. Chagas disease can also spread through contaminated food, a blood transfusion, a donated organ, or from mother to baby during pregnancy. Who is at risk for Chagas disease? Kissing bugs can be found throughout the Americas, but they are more common in certain areas. The people who are most at risk for Chagas disease Live in rural areas of Latin America Have seen the bugs, especially in those areas Have stayed in a house with a thatched roof or with walls that have cracks or crevices What are the symptoms of Chagas disease? In the beginning, there may be no symptoms. Some people do get mild symptoms, such as Fever Fatigue Body aches Headache Loss of appetite Diarrhea Vomiting A rash A swollen eyelid These early symptoms usually go away. However, if you don't treat the infection, it stays in your body. Later, it can cause serious intestinal and heart problems such as An irregular heartbeat that can cause sudden death An enlarged heart that doesn't pump blood well Problems with digestion and bowel movements An increased chance of having a stroke How is Chagas disease diagnosed? A physical exam and blood tests can diagnose it. You may also need tests to see whether the disease has affected your intestines and heart. What are the treatments for Chagas disease? Medicines can kill the parasite, especially early on. You can also treat related problems. For example, a pacemaker helps with some heart complications. Can Chagas disease be prevented? There are no vaccines or medicines to prevent Chagas disease. If you travel to areas where it occurs, you are at higher risk if you sleep outdoors or are staying in poor housing conditions. It is important to use insecticides to prevent bites and practice food safety. Centers for Disease Control and Prevention

MalaCards based summary : Chagas Disease, also known as american trypanosomiasis, is related to trypanosomiasis and meningoencephalitis, and has symptoms including fever and pruritus. An important gene associated with Chagas Disease is IL10 (Interleukin 10), and among its related pathways/superpathways are Chagas disease (American trypanosomiasis) and Innate Immune System. The drugs Aspirin and Warfarin have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and t cells, and related phenotypes are splenomegaly and hepatomegaly

Disease Ontology : 12 A trypanosomiasis that is a tropical parasitic disease caused by the flagellate protozoan Trypanosoma cruzi, which is transmitted to humans and other mammals by an insect vector, the blood-sucking assassin bugs of the subfamily Triatominae (family Reduviidae), most commonly species belonging to the Triatoma, Rhodnius, and Panstrongylus genera. The symptoms include fever, fatigue, body aches, headache, rash, loss of appetite, diarrhea, vomiting, swelling of the eyelids and myocarditis.

NIH Rare Diseases : 52 Chagas disease is caused by the parasite , Trypanosoma cruzi . The triatomine bug, which can carry the parasite, most often bites a person's face and therefore is more commonly known as the "kissing bug". When a triatomine bug infected with Trypanosoma cruzi bites, it can leave behind infected waste which can be spread into the person's eyes, nose, or a wound. Chagas disease can also spread through contaminated food, a blood transfusion , a donated organ , or from mother to baby during pregnancy. Symptoms may include fever, flu-like symptoms, a rash, or swollen eyelid. Early symptoms usually go away without treatment, but can last a few weeks or months. However, if not treated in the early phase, the parasite can become active again years later. In fact, 20-30% of infected people will later develop serious problems affecting their heart, intestines, or espophagus. This risk is greater for those with a weakened immune system . Chagas disease is common in Latin America, but not in the United States. The two drugs used to treat Chagas disease are nifurtimox and benznidazole. On August 30, 2017, the FDA approved benznidazole to treat Chagas disease in children between the ages of 2 to 12 years old. Nifurtimox may also used to treat Chagas disease. Although not FDA approved, nifurtimox can be obtained for the treatment of Chagas disease in the United States through special CDC studies. Similarly, benznidazole is also available through special CDC studies for those with Chagas disease whose treatment is deemed necessary by their doctor but whose age falls outside FDA approval.

CDC : 3 Chagas disease is caused by the parasite Trypanosoma cruzi, which is transmitted to animals and people by insect vectors and is found only in the Americas (mainly, in rural areas of Latin America where poverty is widespread). Chagas disease (T. cruzi infection) is also referred to as American trypanosomiasis. It is estimated that as many as 8 million people living in Mexico, Central America, and South America have Chagas disease, most of whom do not know they are infected. If untreated, infection is lifelong and can be life threatening. The impact of Chagas disease is not limited to only rural areas of Latin America in which vectorborne transmission (diseases transmitted by insects) occurs. Large-scale population movements from rural to urban areas of Latin America and to other regions of the world have increased the geographic distribution and changed the epidemiology of Chagas disease. In the United States and in other regions where Chagas disease is now found but is not endemic, control strategies should focus on preventing transmission from blood transfusion, organ transplantation, and mother-to-baby (congenital transmission).

Wikipedia : 74 Chagas disease, also known as American trypanosomiasis, is a tropical parasitic disease caused by the... more...

Related Diseases for Chagas Disease

Diseases related to Chagas Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 803)
# Related Disease Score Top Affiliating Genes
1 trypanosomiasis 32.6 TNF TLR4 TLR2 NOS2 IL6 IL2
2 meningoencephalitis 31.6 TNF IL6 IL10
3 congestive heart failure 31.5 TNF NPPB IL6 ACE
4 mucocutaneous leishmaniasis 31.4 TNF IL2 IL10 IFNG
5 acute myocarditis 31.2 NPPB IL6 IL10 ACE
6 cysticercosis 31.2 TLR4 IL6 IL1B IL10
7 hypereosinophilic syndrome 31.2 IL2 IL10 IFNG CXCL8
8 myocarditis 31.1 TNF TLR4 NPPB NOS2 IL6 IL2
9 schistosomiasis 31.1 TNF TGFB1 IL2 IL10 IFNG CCL3
10 polyneuropathy 31.1 TNF IL6 IL1B ACE
11 visceral leishmaniasis 31.1 TNF TLR4 TLR2 NOS2 IL2 IL1B
12 immune deficiency disease 31.0 TNF IL6 IL2 IL10 IFNG CCL3
13 exanthem 31.0 TNF IL6 IL2 IL10 CXCL8 ACE
14 esophagitis 31.0 TNF TGFB1 IL6 IL1B IL10 CXCL8
15 cerebrovascular disease 30.9 TNF TLR4 NPPB IL6 ACE
16 autoimmune myocarditis 30.9 TNF IFNG CCL2
17 pericardial effusion 30.9 NPPB IL6 ACE
18 encephalitis 30.9 TNF NOS2 IL6 IL1B IL10 CCL3
19 autoimmune disease 30.9 TNF TGFB1 IL6 IL2 IL1B IL10
20 acquired immunodeficiency syndrome 30.9 TNF NOS2 IL6 IL2 IL1B IL10
21 human immunodeficiency virus type 1 30.8 TNF IL6 IL2 IL10 IFNG CCL3
22 allergic hypersensitivity disease 30.8 TNF TLR4 TLR2 IL2 IL10 IFNG
23 allergic encephalomyelitis 30.8 CCL3 CCL2
24 dengue hemorrhagic fever 30.8 TNF IL6 IL10 IFNG CXCL8
25 myositis 30.8 TNF IL6 IL2 IL1B IFNG CXCL8
26 gastritis 30.8 TNF TLR4 NOS2 IL6 IL1B IL10
27 cutaneous leishmaniasis 30.8 TNF TLR4 TLR2 NOS2 IL6 IL2
28 smallpox 30.7 TNF IL2 IL1B IFNG
29 chikungunya 30.7 TNF IL6 IL1B CCL2
30 peptic ulcer disease 30.7 TNF IL1B IL10 CXCL8
31 gastric ulcer 30.7 TNF IL6 IL1B CXCL8
32 toxoplasmosis 30.7 TNF TLR4 TLR2 TGFB1 NOS2 IL6
33 intracranial hypertension 30.7 TNF NPPB IL1B
34 tetanus 30.7 TNF IL6 IL2 IL1B IL10 IFNG
35 leishmaniasis 30.7 TNF TLR4 TLR2 TGFB1 SRM NOS2
36 systolic heart failure 30.7 TNF NPPB IL6 ACE
37 duodenal ulcer 30.6 TNF TLR4 IL6 IL1B IL10 CXCL8
38 yellow fever 30.6 IL6 IL1B CCL2
39 filarial elephantiasis 30.6 TLR4 TLR2 IL10
40 erythema multiforme 30.6 TNF IL6 IL2 IFNG CXCL8
41 lyme disease 30.6 TNF TLR2 IL6 IL1B CCL3
42 pertussis 30.6 TNF TLR4 IL6 IL1B IL10 CXCL8
43 leprosy 3 30.6 TNF TLR4 TLR2 IL6 IL2 IL1B
44 gastroesophageal reflux 30.6 TNF TGFB1 IL6 IL1B CXCL8 CCL2
45 cardiogenic shock 30.6 NPPB IL6
46 mycobacterium kansasii 30.6 TLR2 CXCL8
47 mixed connective tissue disease 30.6 TNF IL6 IL10 IFNG
48 cellulitis 30.5 TNF IL6 IL10
49 severe combined immunodeficiency 30.5 TGFB1 IL6 IL2 IL10 IFNG
50 endocarditis 30.5 TNF TLR2 IL6 IL10 IFNG CXCL8

Graphical network of the top 20 diseases related to Chagas Disease:



Diseases related to Chagas Disease

Symptoms & Phenotypes for Chagas Disease

Human phenotypes related to Chagas Disease:

58 31 (show all 27)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 splenomegaly 58 31 frequent (33%) Frequent (79-30%) HP:0001744
2 hepatomegaly 58 31 frequent (33%) Frequent (79-30%) HP:0002240
3 fever 58 31 frequent (33%) Frequent (79-30%) HP:0001945
4 dyspnea 58 31 frequent (33%) Frequent (79-30%) HP:0002094
5 arrhythmia 58 31 frequent (33%) Frequent (79-30%) HP:0011675
6 thromboembolism 58 31 frequent (33%) Frequent (79-30%) HP:0001907
7 pallor 58 31 frequent (33%) Frequent (79-30%) HP:0000980
8 abdominal pain 58 31 frequent (33%) Frequent (79-30%) HP:0002027
9 skin rash 58 31 frequent (33%) Frequent (79-30%) HP:0000988
10 myalgia 58 31 frequent (33%) Frequent (79-30%) HP:0003326
11 cough 58 31 frequent (33%) Frequent (79-30%) HP:0012735
12 cardiomyopathy 58 31 frequent (33%) Frequent (79-30%) HP:0001638
13 headache 58 31 frequent (33%) Frequent (79-30%) HP:0002315
14 diarrhea 58 31 frequent (33%) Frequent (79-30%) HP:0002014
15 myocarditis 58 31 frequent (33%) Frequent (79-30%) HP:0012819
16 periorbital edema 58 31 frequent (33%) Frequent (79-30%) HP:0100539
17 lymphadenopathy 58 31 frequent (33%) Frequent (79-30%) HP:0002716
18 localized skin lesion 58 31 frequent (33%) Frequent (79-30%) HP:0011355
19 autoimmune antibody positivity 58 31 frequent (33%) Frequent (79-30%) HP:0030057
20 congestive heart failure 58 31 occasional (7.5%) Occasional (29-5%) HP:0001635
21 aganglionic megacolon 58 31 occasional (7.5%) Occasional (29-5%) HP:0002251
22 achalasia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002571
23 abnormal large intestine physiology 58 31 occasional (7.5%) Occasional (29-5%) HP:0012700
24 encephalitis 58 31 very rare (1%) Very rare (<4-1%) HP:0002383
25 peripheral neuropathy 58 31 very rare (1%) Very rare (<4-1%) HP:0009830
26 abnormality of the nervous system 58 Very rare (<4-1%)
27 edema 58 Frequent (79-30%)

UMLS symptoms related to Chagas Disease:


fever, pruritus

GenomeRNAi Phenotypes related to Chagas Disease according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.88 ACE CXCL8 IL10 IL1B IL2 NOS2
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.88 ACE CXCL8 IL10 IL1B IL2 NOS2

MGI Mouse Phenotypes related to Chagas Disease:

45 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.4 ACE CYP51A1 GSR IFNG IL10 IL1B
2 growth/size/body region MP:0005378 10.32 ACE CYP51A1 IFNG IL10 IL1B IL2
3 immune system MP:0005387 10.3 ACE CCL2 CYP51A1 IFNG IL10 IL1B
4 homeostasis/metabolism MP:0005376 10.29 ACE CYP51A1 IFNG IL10 IL1B IL2
5 digestive/alimentary MP:0005381 10.28 CYP51A1 IFNG IL10 IL2 IL6 NOS2
6 hematopoietic system MP:0005397 10.27 ACE IFNG IL10 IL1B IL2 IL6
7 endocrine/exocrine gland MP:0005379 10.22 ACE IFNG IL10 IL2 IL6 NOS2
8 craniofacial MP:0005382 10.15 CYP51A1 IFNG IL10 IL1B NOS2 SMAD2
9 liver/biliary system MP:0005370 10.14 ACE IFNG IL10 IL2 IL6 NOS2
10 integument MP:0010771 10.13 IFNG IL10 IL1B IL6 NOS2 SMAD2
11 adipose tissue MP:0005375 10.11 ACE IL6 NOS2 TGFB1 TLR2 TLR4
12 neoplasm MP:0002006 10.1 ACE IFNG IL10 IL1B IL2 IL6
13 muscle MP:0005369 10.02 CYP51A1 IFNG IL10 IL6 NOS2 TGFB1
14 reproductive system MP:0005389 9.96 ACE IFNG IL10 IL2 IL6 NOS2
15 respiratory system MP:0005388 9.85 IFNG IL10 IL2 IL6 NOS2 SMAD2
16 skeleton MP:0005390 9.7 CYP51A1 IFNG IL10 IL1B IL6 NOS2
17 vision/eye MP:0005391 9.32 GSR IFNG IL10 IL2 IL6 NOS2

Drugs & Therapeutics for Chagas Disease

Drugs for Chagas Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 96)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
2
Warfarin Approved Phase 4 81-81-2 6691 54678486
3
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
4
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
5
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 11128-99-7, 4474-91-3 172198
6
Enalaprilat Approved Phase 4 76420-72-9 6917719
7
Coumarin Experimental Phase 4 91-64-5 323
8 Fibrinolytic Agents Phase 4
9 Platelet Aggregation Inhibitors Phase 4
10 Analgesics, Non-Narcotic Phase 4
11 Antipyretics Phase 4
12 Anti-Inflammatory Agents, Non-Steroidal Phase 4
13 Analgesics Phase 4
14 Cyclooxygenase Inhibitors Phase 4
15 Anti-Inflammatory Agents Phase 4
16 Anticoagulants Phase 4
17 HIV Protease Inhibitors Phase 4
18
protease inhibitors Phase 4
19 Angiotensin Receptor Antagonists Phase 4
20 Angiotensin II Type 1 Receptor Blockers Phase 4
21 Giapreza Phase 4
22 Angiotensinogen Phase 4
23 Angiotensin-Converting Enzyme Inhibitors Phase 4
24 LCZ 696 Phase 4
25 Antihypertensive Agents Phase 4
26
Bisoprolol Approved Phase 3 66722-44-9 2405
27
Selenium Approved, Investigational, Vet_approved Phase 3 7782-49-2
28
Amiodarone Approved, Investigational Phase 3 1951-25-3 2157
29
Coal tar Approved Phase 3 8007-45-2
30
Ornithine Approved, Nutraceutical Phase 3 3184-13-2, 70-26-8 6262
31 Nifurtimox Investigational Phase 3 23256-30-6
32 Melarsoprol Investigational Phase 3 494-79-1
33 Immunosuppressive Agents Phase 2, Phase 3
34 Benzonidazole Phase 2, Phase 3
35 Sympatholytics Phase 3
36 Adrenergic Antagonists Phase 3
37 Adrenergic beta-1 Receptor Antagonists Phase 3
38 Adrenergic beta-Antagonists Phase 3
39 Neurotransmitter Agents Phase 3
40 Autonomic Agents Phase 3
41 Adrenergic Agents Phase 3
42 Cytochrome P-450 Enzyme Inhibitors Phase 3
43 Protective Agents Phase 3
44 Sodium Selenite Phase 3
45 Antioxidants Phase 3
46 Cytochrome P-450 CYP3A Inhibitors Phase 3
47 Anti-Arrhythmia Agents Phase 3
48 Sodium Channel Blockers Phase 3
49 Potassium Channel Blockers Phase 3
50 Vasodilator Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 79)
# Name Status NCT ID Phase Drugs
1 CHADSS: Chagas Disease Scan Study Unknown status NCT01650792 Phase 4 Aspirin
2 Population Pharmacokinetics in Benznidazole-treated Adults With Chronic Chagas Disease. Benznidazole Pharmacokinetics and Adverse Reactions Relationship. Completed NCT01755403 Phase 4 Benznidazole
3 A Randomized Trial of the Effects of Exercise Training in Chagas Cardiomyopathy Completed NCT01006473 Phase 4
4 Optimization of Sampling Procedure for PCR Technique to Assess Parasitological Response for Patients With Chronic Chagas Disease Treated With Benznidazole in Aiquile, Bolivia Completed NCT01678599 Phase 4 Benznidazole
5 Evaluation of Impact of the Implantation of an Anticoagulation Clinic in an University Hospital in Brazil Completed NCT01006486 Phase 4
6 Population Pharmacokinetics Study of Benznidazole in Children With Chagas'Disease Completed NCT01549236 Phase 4 Benznidazole 12,5mg or 100mg
7 A Multicenter, Prospective, Randomized, Open-label, Blinded-endpoint, Phase 4 Study to Evaluate the Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With Chronic Chagas' Cardiomyopathy Not yet recruiting NCT04023227 Phase 4 Sacubitril/valsartan;Enalapril
8 Reveal Chagas: Clinical Evidence of the Implantable Cardiac Monitor in Patients With Chagas Disease Terminated NCT01539161 Phase 4
9 Benznidazole Evaluation for Interrupting Trypanosomiasis - The BENEFIT Trial Unknown status NCT00123916 Phase 3 Benznidazole;Placebo
10 Cardiovascular Health Investigation and Collaboration From Countries of America to Assess the Markers and Outcomes of Chagas Disease (CHICAMOCHA-3) - EQUITY (Equivalence of Usual Interventions for Trypanosomiasis) Unknown status NCT02369978 Phase 2, Phase 3 Nifurtimox;Benznidazole;Placebo
11 Etiologic Treatment With Benznidazole in Adult Patients With Chronic Chagas Disease. A Randomized Double Blind Clinical Trial Completed NCT02386358 Phase 3 Benznidazole;Placebo
12 Impact of a Physical Exercise Program in Cardiopulmonary RehAbilitation In Patients With Chronic Chagas Heart Disease: a Randomized Controlled Trial (PEACH Trial) Completed NCT02517632 Phase 3
13 Cardiac Rehabilitation Program in Patients With Chagas Heart Failure: a Pilot Study Completed NCT02516293 Phase 2, Phase 3
14 A Randomized Double-blind Placebo Force-titration Controlled Study With Bisoprolol in Patients With Chronic Heart Failure Secondary to Chagas´ Cardiomyopathy. Completed NCT00323973 Phase 3 Bisoprolol
15 Clinical Study Comparing the Nifurtimox-Eflornithine Combination With the Standard Eflornithine Regimen for the Treatment of Trypanosoma Brucei Gambiense Human African Trypanosomiasis in the Meningoencephalitic Phase Completed NCT00146627 Phase 3 Eflornithine;Nifurtimox
16 Short-course Benznidazole Treatment to Reduce Trypanosoma Cruzi Parasitic Load in Women of Reproductive Age: A Non-inferiority Randomized Controlled Trial Recruiting NCT03672487 Phase 3 Benznidazole;Placebo Oral Tablet
17 Selenium Treatment and Chagasic Cardiopathy (STCC): A Prospective Randomized Trial in Patients With Chagas Disease Recruiting NCT00875173 Phase 3 Selenium;Placebo (for Selenium)
18 A Trial Testing Amiodarone in Chagas Cardiomyopathy (ATTACH) Recruiting NCT03193749 Phase 3 Amiodarone Hydrochloride;Placebo Oral Tablet
19 Prospective, Historically Controlled Study to Evaluate the Efficacy and Safety of a New Pediatric Formulation of Nifurtimox in Children Aged 0 to 17 Years With Chagas' Disease Active, not recruiting NCT02625974 Phase 3 Nifurtimox (Lampit, BAYA2502);Placebo
20 Prospective, Single-arm, Multicentre Study, Using a Historical Control, to Evaluate the Efficacy/Safety and Population Pharmacokinetics of Benznidazole in Children With Chronic Indeterminate Chagas Disease Not yet recruiting NCT04024163 Phase 3 Benznidazole
21 Multicenter Randomized Study Of Cell Therapy In Cardiopathies - Chagas Cardiomyopathy Terminated NCT00349271 Phase 3 Filgrastime (G-CSF);Standart therapy
22 Clinical Trial Comparing the Therapeutic Combinations Melarsoprol-Nifurtimox, Melarsoprol-Eflornithine and Eflornithine-Nifurtimox in the Treatment of Gambiense Human African Trypanosomiasis in the Meningo-Encephalitic Phase Terminated NCT00330148 Phase 3 melarsoprol 1.8 mg/kg/d, 10d + nifurtimox 15/20 mg/kg/d, 10d;melarsoprol 1.8 mg/kg/d, 10d + eflornithine 400 mg/kg/d, 7d;nifurtimox 15/20 mg/kg/d 10d + eflornithine 400 mg/kg/d 7d
23 Phase II Clinical Trial for the Evaluation of Different Benznidazole Regimens for the Treatment of Chronic Chagas Disease in Adult Patients. Berenice Project Unknown status NCT03191162 Phase 2 Benznidazole
24 Prospective, Double-blind, Randomized, Placebo-controlled Phase II Clinical Trial for Evaluation of G-CSF in Patients With Chronic Chagas Cardiomyopathy Unknown status NCT02154269 Phase 2 Treatment with G-CSF (Granulocyte colony stimulating factor);Placebo saline
25 Phase 2 Randomized, Multicenter, Placebo-controlled, Safety and Efficacy Study to Evaluate Three Oral E1224 Dosing Regimens and Benznidazole for the Treatment of Adult Patients With Chronic Indeterminate Chagas Disease Unknown status NCT01489228 Phase 2 E1224;Benznidazole;Placebo
26 Phase 2, Randomized, Multicenter, Placebo-controlled, Safety and Efficacy Study to Evaluate Six Oral Fexinidazole Dosing Regimens for the Treatment of Adult Patients With Chronic Indeterminate Chagas Disease. Unknown status NCT02498782 Phase 2 Fexinidazole;Placebo
27 Phase 2 Randomized, Multicenter, Safety and Efficacy Trial to Evaluate Different Oral Benznidazole Monotherapy and Benznidazole/E1224 Combination Regimens for the Treatment of Adult Patients With Chronic Indeterminate Chagas Disease Unknown status NCT03378661 Phase 2 Benznidazole;E1224;E1224 Placebo;Benznidazole Placebo
28 PROTOCOL FOR PHASE II CLINICAL TRIAL, RANDOMIZED AND OPEN FOR ETIOLOGICAL TREATMENT OF CHRONIC CHAGAS DISEASE WITH POSACONAZOLE AND BENZNIDAZOLE Completed NCT01162967 Phase 2 Benznidazole;Posaconazole
29 Phase 2 Proof-of-Activity Study of Oral Posaconazole in the Treatment of Asymptomatic Chronic Chagas Disease (Phase 2, Protocol No. P05267) Completed NCT01377480 Phase 2 Posaconazole;Placebo for posaconazole;Benznidazole
30 The Effects of Autologous Intracoronary Stem Cell Transplantation In Patients With End-Stage Dilated Cardiomyopathy Completed NCT00629018 Phase 2 Bone Marrow Stimulation
31 Phase 2 Randomized, Multicenter, Double-blinded Safety and Efficacy Study to Evaluate Oral Fexinidazole Dosing Regimens for the Treatment of Adult Patients With Chronic Indeterminate Chagas Disease Recruiting NCT03587766 Phase 2 Fexinidazole;Placebo Oral Tablet
32 Effect of Colchicine on Inflammation and Myocardial Fibrosis Assessed by Magnetic Resonance Imaging in Patients With Chagas' Heart Disease Recruiting NCT03704181 Phase 2 Colchicine 0.5 MG twice day for one year;Placebo Oral Tablet
33 A Phase II Trial of Nifurtimox for Refractory or Relapsed Neuroblastoma or Medulloblastoma. Active, not recruiting NCT00601003 Phase 2 Nifurtimox;Cyclophosphamide;Topotecan
34 New Chemotherapy Regimens and Biomarkers for Chagas Disease Not yet recruiting NCT03981523 Phase 2 Benznidazole;Nifurtimox
35 Phase II Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant Terminated NCT01174082 Phase 2 GM-CSF
36 Open Label, Randomized, Single Dose Cross-over Study to Assess Bioequivalence Between Single 120 mg Nifurtimox Tablet and Four 30 mg Nifurtimox Tablets Administered Orally, Following High Calorie/High Fat Meal to Adult Male and Female Patients Suffering From Chronic Chagas' Disease and to Determine the Pharmacokinetics of Nifurtimox Tablets Administered Orally, in a Form of Aqueous Slurry Completed NCT01927224 Phase 1 Nifurtimox (BAYa2502) (4 x 30 mg tablet);Nifurtimox (BAYa2502) (slurry of 4 x 30 mg tablets in tap water);Nifurtimox (BAYa2502) (120 mg tablet)
37 Non-blinded, Randomized, Single Center, Single Dose, Cross-over Study to Assess the Effect of a High Calorie/High Fat Meal on the Pharmacokinetics of Four 30 mg Nifurtimox Tablets Taken Orally by Adult Male and Female Patients Suffering From Chronic Chagas' Disease Completed NCT02606864 Phase 1 Nifurtimox (BAYa2502)
38 Open Label, Randomized, Single-dose, Cross-over Study to Evaluate the Relative Bioavailability, Safety, and Tolerability of Single Doses of Nifurtimox 30 mg Tablets Exhibiting Different in Vitro Dissolution Characteristics, and to Evaluate the Relative Bioavailability of Nifurtimox 30 mg and 120 mg Tablets, Administered to Adult Male and Female Patients With Chagas' Disease Completed NCT03350295 Phase 1 Nifurtimox (Lampit, BAYA2502)
39 A Phase 1 Pharmacokinetic Drug-Drug Interaction Study of Benznidazole and E1224 in Healthy Male Volunteers Completed NCT03892213 Phase 1 Benznidazole;E1224
40 Open-label, Randomized, Single-dose, Cross-over Study to Assess Bioequivalence Between a Single 120 mg Nifurtimox Tablet and a Newly Developed 120 mg Nifurtimox Tablet, Administered Orally Under Fed Conditions to Adult Male and Female Patients With Chronic Chagas' Disease Completed NCT03708133 Phase 1 Nifurtimox (Lampit, BAYA2502)_Test;Nifurtimox (Lampit, BAYA2502)_Reference
41 Open-label, Randomized, Single-dose, Cross-over Study to Evaluate the Influence of Dietary Habits on the Pharmacokinetics, Safety, and Tolerability of a 120 mg Dose and to Assess the Relative Bioavailability of a 240 mg Dose of Nifurtimox Tablets Administered to Adult Male and Female Patients With Chagas' Disease Active, not recruiting NCT03334838 Phase 1 Nifurtimox (Lampit, BAYA2502)
42 Effects of Physical Training on Sensitivity Baroreflex Patients Without Chagas' Heart Ventricular Systolic Dysfunction Unknown status NCT02295215
43 Transcatheter Renal Denervation in Patients With Systolic Heart Failure Due to Chagas' Disease - a Safety and Efficacy Study. Unknown status NCT02099903
44 EPIcardial and Endocardial Mapping and Ablation Using Contact Force Catheter in Chagasic Patients With Sustained Ventricular Tachycardia Unknown status NCT01847378
45 Impact of The Pharmaceutical Care on the Quality of Life of Patients With Chagas Disease and Heart Failure: Randomized Clinical Trial Unknown status NCT01566617
46 CHronic Use of Amiodarone aGAinSt Implantable Cardioverter-defibrillator Therapy for Primary Prevention of Death in Patients With Chagas Cardiomyopathy Study (CHAGASICS) Unknown status NCT01722942 amiodarone hydrochloride
47 Measurement of Antibodies in Adults With a History of Kawasaki Disease Unknown status NCT02853266
48 Laparoscopy Heller Myotomy With Fundoplication Associated Versus Peroral Endoscopic Myotomy (POEM) Unknown status NCT02138643
49 Abbott ESA Chagas Assay Post-Market Study Completed NCT01662362
50 Assessment of Speckle Tracking Strain Predictive Value for Myocardial Fibrosis in Subjects With Chagas Disease Completed NCT02327052

Search NIH Clinical Center for Chagas Disease

Cochrane evidence based reviews: chagas disease

Genetic Tests for Chagas Disease

Anatomical Context for Chagas Disease

MalaCards organs/tissues related to Chagas Disease:

40
Heart, Testes, T Cells, Colon, Eye, Bone, Brain

Publications for Chagas Disease

Articles related to Chagas Disease:

(show top 50) (show all 11316)
# Title Authors PMID Year
1
Chagas disease: still a neglected emergency. 61 42
31690431 2019
2
Association of vitamin D3, VDR gene polymorphisms, and LL-37 with a clinical form of Chagas Disease. 61 42
31508781 2019
3
Trypanosoma cruzi: the early contact between insect-derived metacyclic trypomastigotes and the mammalian cells 42
31578843 2019
4
Synthesis and characterization of potent inhibitors of Trypanosoma cruzi dihydrofolate reductase. 54 61
20452776 2010
5
Second generation analogues of the cancer drug clinical candidate tipifarnib for anti-Chagas disease drug discovery. 61 54
20429511 2010
6
Plasma ACE2 activity is an independent prognostic marker in Chagas' disease and equally potent as BNP. 54 61
20142028 2010
7
Amino-terminal fragment of C-type natriuretic peptide precursor and C-type natriuretic peptide do not correlate in patients with Chagas disease: role for neutral endopeptidase. 54 61
20090473 2010
8
Trypanosoma cruzi calreticulin: a possible role in Chagas' disease autoimmunity. 61 54
19108895 2009
9
Human autoantibodies specific for neurotrophin receptors TrkA, TrkB, and TrkC protect against lethal Trypanosoma cruzi infection in mice. 54 61
18832578 2008
10
Mapping of the conserved antigenic domains shared between potato apyrase and parasite ATP diphosphohydrolases: potential application in human parasitic diseases. 61 54
18598576 2008
11
Auto-antibodies to receptor tyrosine kinases TrkA, TrkB and TrkC in patients with chronic Chagas' disease. 54 61
18410251 2008
12
The Chagas' disease parasite Trypanosoma cruzi exploits nerve growth factor receptor TrkA to infect mammalian hosts. 61 54
18005706 2007
13
Evaluation of asymptomatic patients with chronic Chagas disease through ambulatory electrocardiogram, echocardiogram and B-Type natriuretic peptide analyses. 61 54
17057935 2006
14
Development and characterization of an immobilized enzyme reactor (IMER) based on human glyceraldehyde-3-phosphate dehydrogenase for on-line enzymatic studies. 54 61
16297925 2006
15
Brain natriuretic peptide based strategy to detect left ventricular dysfunction in Chagas disease: a comparison with the conventional approach. 54 61
16023747 2006
16
Retinal dysfunction in patients with chronic Chagas' disease is associated to anti-Trypanosoma cruzi antibodies that cross-react with rhodopsin. 54 61
16423878 2006
17
Genetic diversity and kinetic properties of Trypanosoma cruzi dihydroorotate dehydrogenase isoforms. 54 61
16172019 2006
18
CYP51 from Trypanosoma cruzi: a phyla-specific residue in the B' helix defines substrate preferences of sterol 14alpha-demethylase. 61 54
16321980 2006
19
Type 1 chemokine receptor expression in Chagas' disease correlates with morbidity in cardiac patients. 54 61
16299288 2005
20
Placental alkaline phosphatase (PLAP) enzyme activity and binding to IgG in Chagas' disease. 61 54
16122790 2005
21
Specific human antibodies do not inhibit Trypanosoma cruzi oligopeptidase B and cathepsin B, and immunoglobulin G enhances the activity of trypomastigote-secreted oligopeptidase B. 54 61
15784182 2005
22
Brain natriuretic peptide predicts survival in Chagas' disease more effectively than atrial natriuretic peptide. 54 61
15710733 2005
23
[Measurement of human brain natriuretic peptide in patients with Chagas' disease]. 61 54
15761636 2005
24
Kinetics of expression of the salivary apyrases in Triatoma infestans. 61 54
15475299 2004
25
Chagas' disease parasite promotes neuron survival and differentiation through TrkA nerve growth factor receptor. 54 61
15447671 2004
26
Phenotypic and functional characteristics of CD28+ and CD28- cells from chagasic patients: distinct repertoire and cytokine expression. 61 54
15196253 2004
27
Elevated concentrations of CCL2 and tumor necrosis factor-alpha in chagasic cardiomyopathy. 54 61
15034825 2004
28
Role of calreticulin from parasites in its interaction with vertebrate hosts. 54 61
15128045 2004
29
PDNF, a human parasite-derived mimic of neurotrophic factors, prevents caspase activation, free radical formation, and death of dopaminergic cells exposed to the Parkinsonism-inducing neurotoxin MPP+. 61 54
14597229 2003
30
Brain natriuretic peptide in Chagas' disease: further insights. 54 61
12892979 2003
31
Brain natriuretic peptide as a predictor of cardiomyopathy in Chagas' disease. 61 54
12737906 2003
32
Polyamine biosynthetic enzymes as drug targets in parasitic protozoa. 54 61
12653650 2003
33
Brain natriuretic peptide and left ventricular dysfunction in Chagas' disease. 54 61
12241721 2002
34
Analysis of the T-cell receptor beta-chain variable-region (Vbeta) repertoire in chronic human Chagas' disease. 61 54
12366778 2002
35
Chemokine receptor CCR5 polymorphisms and Chagas' disease cardiomyopathy. 54 61
11703822 2001
36
HLA and beta-myosin heavy chain do not influence susceptibility to Chagas disease cardiomyopathy. 54 61
10955954 2000
37
Autoantibodies against the beta- and muscarinic receptors in cardiomyopathy. 54 61
10904849 2000
38
Nitrofuran drugs as common subversive substrates of Trypanosoma cruzi lipoamide dehydrogenase and trypanothione reductase. 61 54
10571254 1999
39
Trypanosoma cruzi has not lost its S-adenosylmethionine decarboxylase: characterization of the gene and the encoded enzyme. 61 54
9677309 1998
40
Overlapping substrate specificities of cytochrome P450 3A and P-glycoprotein for a novel cysteine protease inhibitor. 61 54
9531525 1998
41
Trypanosoma cruzi glycosomal glyceraldehyde-3-phosphate dehydrogenase: structure, catalytic mechanism and targeted inhibitor design. 61 54
9580189 1998
42
Desensitization and sequestration of human m2 muscarinic acetylcholine receptors by autoantibodies from patients with Chagas' disease. 61 54
9148906 1997
43
Chagasic patients lack CD28 expression on many of their circulating T lymphocytes. 61 54
8560201 1996
44
Trypanosoma cruzi acidic ribosomal P protein gene family. Novel P proteins encoding unusual cross-reactive epitopes. 54 61
7693813 1993
45
Suppression by Trypanosoma cruzi of T-cell receptor expression by activated human lymphocytes. 54 61
1427979 1992
46
Cloning and expression of Trypanosoma cruzi ribosomal protein P0 and epitope analysis of anti-P0 autoantibodies in Chagas' disease patients. 61 54
1377223 1992
47
A structure-based approach towards the identification of novel antichagasic compounds: Trypanosoma cruzi carbonic anhydrase inhibitors. 61
31619095 2020
48
The effect of benznidazole dose among the efficacy outcome in the murine animal model. A quantitative integration of the literature. 61
31610148 2020
49
Molecular eco-epidemiology on the sympatric Chagas disease vectors Triatoma brasiliensis and Triatoma petrocchiae: Ecotopes, genetic variation, natural infection prevalence by trypanosomatids and parasite genotyping. 61
31545949 2020
50
Structure-activity relationship of 4-azaindole-2-piperidine derivatives as agents against Trypanosoma cruzi. 61
31706667 2020

Variations for Chagas Disease

Expression for Chagas Disease

Search GEO for disease gene expression data for Chagas Disease.

Pathways for Chagas Disease

Pathways related to Chagas Disease according to KEGG:

36
# Name Kegg Source Accession
1 Chagas disease (American trypanosomiasis) hsa05142

Pathways related to Chagas Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 98)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.15 TNF TLR4 TLR2 TGFB1 NOS2 IL6
2
Show member pathways
13.95 TNF TGFB1 SMAD2 NOS2 IL6 IL2
3
Show member pathways
13.82 TNF TLR4 TGFB1 NOS2 IL6 IL2
4
Show member pathways
13.69 TNF TGFB1 SMAD2 IL6 IL2 IL1B
5
Show member pathways
13.57 TNF TLR4 TLR2 TGFB1 IL6 IL2
6
Show member pathways
13.53 TNF TGFB1 NOS2 IL6 IL2 IL1B
7
Show member pathways
13.44 TNF TGFB1 IL6 IL2 IL1B IL10
8
Show member pathways
13.11 TNF TLR4 TLR2 IL6 IL1B CXCL8
9
Show member pathways
13.03 TNF TGFB1 IL6 IL2 IL1B IL10
10 13 TGFB1 SMAD2 NOS2 IL6 IL2 IFNG
11
Show member pathways
12.99 TNF TLR4 TLR2 IL6 IL2 IL1B
12 12.93 TNF TLR2 IL6 IL1B IFNG CCL2
13
Show member pathways
12.89 TNF TLR4 IL6 IL1B IFNG CXCL8
14
Show member pathways
12.88 TNF TLR4 TLR2 TGFB1 IL6 IL2
15
Show member pathways
12.81 TNF TLR4 TLR2 TGFB1 IL6 IL2
16
Show member pathways
12.78 TNF NOS2 IL6 IL2 IL1B IL10
17
Show member pathways
12.77 TNF TLR4 TLR2 TGFB1 SMAD2 IL6
18 12.75 TNF TLR2 IL2 IL1B IL10 IFNG
19
Show member pathways
12.55 TNF TLR2 IL6 IL1B IFNG CXCL8
20
Show member pathways
12.54 TNF IL6 IL2 IL10 CXCL8 CCL3
21
Show member pathways
12.54 TNF IL6 IL2 IL1B IFNG GSR
22
Show member pathways
12.53 TNF TLR4 NOS2 IL6 IL1B IFNG
23 12.48 TNF TGFB1 SMAD2 IL6 IL2
24
Show member pathways
12.48 TNF TLR4 TLR2 TGFB1 NOS2 IL1B
25
Show member pathways
12.46 TNF TGFB1 IL6 IL2 IL1B IL10
26 12.45 TNF TLR4 IL1B CXCL8
27 12.45 TNF TLR4 TLR2 TGFB1 SMAD2
28
Show member pathways
12.44 IL6 IL2 IL10 IFNG
29 12.44 TNF TLR4 IL6 IL1B CXCL8
30 12.44 TNF TLR4 IL6 IL1B CXCL8 CCL2
31
Show member pathways
12.43 TNF TLR4 TLR2 TGFB1 SMAD2 NOS2
32
Show member pathways
12.42 TNF TLR2 NOS2 IL6 IL1B CXCL8
33 12.42 TNF TLR4 TLR2 TGFB1 SMAD2 NOS2
34
Show member pathways
12.41 TNF TLR4 TLR2 IL6 CXCL8
35
Show member pathways
12.41 TNF TLR4 TLR2 NOS2 IL6 IL1B
36 12.39 TNF TLR4 TLR2 TGFB1 NOS2 IL6
37
Show member pathways
12.37 TNF IL6 IL2 IL1B IL10
38
Show member pathways
12.34 TNF TGFB1 IL6 ACE
39 12.34 TNF IL6 IL1B IL10 CXCL8
40
Show member pathways
12.31 TNF TLR4 IL1B IFNG
41 12.28 TGFB1 SMAD2 IL6 CXCL8
42
Show member pathways
12.25 TNF TLR4 TLR2 IL6 IL1B IFNG
43
Show member pathways
12.22 TNF TLR4 TLR2 TGFB1 SMAD2 IL6
44 12.21 TNF IL1B IFNG CCL2
45 12.21 TNF TLR4 IL6 IL2 IL1B IL10
46 12.18 TNF IL6 IL2 IL10 IFNG
47 12.17 TNF TGFB1 IL1B IFNG
48
Show member pathways
12.17 NOS2 IL2 IL1B IFNG CCL3
49 12.17 TNF TGFB1 NOS2 IL6 IL1B IL10
50
Show member pathways
12.16 TLR4 TLR2 IL2 IL1B

GO Terms for Chagas Disease

Cellular components related to Chagas Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.73 TNF TGFB1 NPPB IL6 IL2 IL1B
2 extracellular space GO:0005615 9.4 TNF TGFB1 NPPB IL6 IL2 IL1B

Biological processes related to Chagas Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 87)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.4 TLR4 TLR2 TGFB1 IL6 IL1B IL10
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.29 TNF TLR4 TLR2 TGFB1 SMAD2 IL6
3 positive regulation of transcription, DNA-templated GO:0045893 10.22 TNF TGFB1 SMAD2 IL6 IL1B IL10
4 negative regulation of cell proliferation GO:0008285 10.13 TLR2 TGFB1 SMAD2 IL6 IL1B IL10
5 positive regulation of ERK1 and ERK2 cascade GO:0070374 10.09 TNF TLR4 TGFB1 CCL3 CCL2
6 positive regulation of protein phosphorylation GO:0001934 10.07 TNF TGFB1 IL2 IL1B IFNG
7 MAPK cascade GO:0000165 10.07 TNF TGFB1 IL2 IL1B CCL3 CCL2
8 regulation of cell proliferation GO:0042127 10.06 TNF TGFB1 TCFL5 NOS2
9 response to lipopolysaccharide GO:0032496 10.06 TLR4 TLR2 NOS2 IL1B IL10
10 positive regulation of DNA-binding transcription factor activity GO:0051091 10.02 TNF IL6 IL1B IL10
11 negative regulation of gene expression GO:0010629 10.02 TNF TGFB1 SMAD2 NOS2 IFNG CCL3
12 positive regulation of gene expression GO:0010628 10.02 TNF TLR4 TLR2 TGFB1 SMAD2 IL6
13 neutrophil chemotaxis GO:0030593 9.99 IL1B CXCL8 CCL3 CCL2
14 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.99 TNF IL6 IL2 IFNG
15 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.99 TNF TLR4 TLR2 TGFB1 IL6 IL1B
16 regulation of insulin secretion GO:0050796 9.97 TNF NOS2 IL1B IFNG
17 cellular response to interferon-gamma GO:0071346 9.97 TLR4 TLR2 NOS2 CCL3 CCL2
18 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.96 TNF TLR4 TLR2 IL1B
19 inflammatory response GO:0006954 9.96 TNF TLR4 TLR2 TGFB1 IL6 IL1B
20 cellular response to organic cyclic compound GO:0071407 9.95 TNF TGFB1 IL1B CCL3 CCL2
21 chemokine-mediated signaling pathway GO:0070098 9.94 CXCL8 CCL3 CCL2
22 response to glucocorticoid GO:0051384 9.94 TNF IL6 IL10
23 humoral immune response GO:0006959 9.94 TNF IL6 IFNG CCL2
24 positive regulation of T cell proliferation GO:0042102 9.93 IL6 IL2 IL1B
25 positive regulation of tumor necrosis factor production GO:0032760 9.92 TLR4 TLR2 CCL3
26 negative regulation of fat cell differentiation GO:0045599 9.92 TNF TGFB1 IL6
27 cellular response to lipopolysaccharide GO:0071222 9.92 TNF TLR4 NOS2 IL6 IL1B IL10
28 positive regulation of phagocytosis GO:0050766 9.91 TNF IL1B IFNG
29 extrinsic apoptotic signaling pathway GO:0097191 9.91 TNF TGFB1 IFNG
30 monocyte chemotaxis GO:0002548 9.91 IL6 CCL3 CCL2
31 positive regulation of epithelial to mesenchymal transition GO:0010718 9.91 TGFB1 SMAD2 IL6 IL1B
32 positive regulation of nitric oxide biosynthetic process GO:0045429 9.91 TNF TLR4 IL1B IFNG
33 positive regulation of protein complex assembly GO:0031334 9.9 TNF TGFB1 IFNG
34 negative regulation of mitotic cell cycle GO:0045930 9.9 TNF TGFB1 IL10
35 negative regulation of interleukin-6 production GO:0032715 9.9 TNF TLR4 IL10
36 positive regulation of JAK-STAT cascade GO:0046427 9.9 TNF IL6 IL10
37 positive regulation of interferon-gamma production GO:0032729 9.9 TNF TLR4 IL2 IL1B
38 immune response GO:0006955 9.9 TNF TLR4 TLR2 IL6 IL2 IL1B
39 positive regulation of vascular endothelial growth factor production GO:0010575 9.89 TGFB1 IL6 IL1B
40 microglial cell activation GO:0001774 9.89 TNF TLR2 IFNG
41 negative regulation of neurogenesis GO:0050768 9.89 TNF IL6 IL1B
42 positive regulation of interleukin-12 production GO:0032735 9.89 TLR4 TLR2 IFNG
43 positive regulation of interleukin-6 production GO:0032755 9.89 TNF TLR4 TLR2 IL6 IL1B
44 positive regulation of interleukin-6 secretion GO:2000778 9.88 TNF TLR4 TLR2 IL1B
45 positive regulation of inflammatory response GO:0050729 9.88 TNF TLR4 TLR2 IL2 IL1B CCL3
46 positive regulation of glial cell proliferation GO:0060252 9.87 TNF IL6 IL1B
47 astrocyte activation GO:0048143 9.86 TNF IL1B IFNG
48 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.86 TNF IL1B IFNG
49 positive regulation of interleukin-8 production GO:0032757 9.86 TNF TLR4 TLR2 IL1B
50 regulation of regulatory T cell differentiation GO:0045589 9.85 TGFB1 IL2 IFNG

Molecular functions related to Chagas Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.46 TGFB1 IL6 IL2 IL10
2 chemokine activity GO:0008009 9.43 CXCL8 CCL3 CCL2
3 type I transforming growth factor beta receptor binding GO:0034713 9.32 TGFB1 SMAD2
4 cytokine activity GO:0005125 9.32 TNF TGFB1 IL6 IL2 IL1B IL10
5 lipopolysaccharide receptor activity GO:0001875 8.96 TLR4 TLR2

Sources for Chagas Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....